@JimHB_4Liberty Here are two 'technical' papers on this 'technology'. https://t.co/5mnfiHRl95 and https://t.co/M4zd1OWUkL Science sounding verbal diarrhea-circular referencing to make it look science.
@skathire @GLettre @bloodgenes @joelhirschhorn @JianXuLab 8/ In 2013-2015, @danielevanbauer, Orkin & team used genetics, TALENs, and then CRISPR to map the BCL11A locus, identifying an erythroid enhancer that, when edited, resulted in less BCL11A + mo
Clinical trial saying everyone was cured (oh by the way...): https://t.co/bfByajC3Ub Shows that CRISPRs can be a therapy in these diseases: https://t.co/b2duzoSyMw Lays groundwork for putzing with BCL11A: https://t.co/krouKQD03a
@planet4589 Your paper "Chromatin stretch enhancer states drive (...)" was cited by Canver, Matthew C. et al.: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/ZnIb69DWdq
RT @UrnovFyodor: Wk10 in @berkeleyMCB grad class on "Impactful CRISPR": therapeutics 1. Why this paper: Cas-based discovery of target for C…
RT @UrnovFyodor: Wk10 in @berkeleyMCB grad class on "Impactful CRISPR": therapeutics 1. Why this paper: Cas-based discovery of target for C…
Wk10 in @berkeleyMCB grad class on "Impactful CRISPR": therapeutics 1. Why this paper: Cas-based discovery of target for CRISPR's biggest clinical success to date (15 pts with thalassemia and 7 pts with SCD are free of major disease symptoms post-editing).
【参考文献2】 Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia https://t.co/aBb6dYL0QG BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/xhiWKW1xml
Saturation mutagenesis (2015) identified critical BCL11A regulatory elements in humans and mice. "Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction."
@Eileen_Furlong @rfriedman22 @EKFarley @sbarolo @ArnostiDavid @JustinMCrocker @timothy_fuqua @mahonylab Plus BCL11A erythroid enhancer in human and mouse: https://t.co/YzWVc93vXT
8/ In 2013-2015, @danielevanbauer, Orkin & team used genetics, TALENs, and then CRISPR to map the BCL11A locus, identifying an erythroid enhancer that, when edited, resulted in less BCL11A + more HbF. Next step: CRISPR therapy. https://t.co/dfi4bI7V
#Genomics2020 TR, discussing high throughput genome editing screen of BCL11A https://t.co/tadi824boO, and epigenome editing https://t.co/osN4rPPa5z, a lot of flexibility on how this can be used, reviewed in https://t.co/S1PHkFOVN4
RT @Festivus159: @Doceletaxel $SGMO's strategy is to target BCL11A's enhancer that is erythroid lineage specific: https://t.co/5f05yzdEKJ
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. https://t.co/gHCd9w13LQ
タイトル避けしてたんだけど薦められて斜め読みしたらすごかった|BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/hsWzuytJeG
BCL11A enhancer dissection by Cas9- mediated in situ saturating mutagenesis! https://t.co/cjcbgUa7U9
Nature ハイライト:<i>BCL11A</i>エンハンサーの破壊解析 | Nature | Nature Publishing Group: https://t.co/VelkoKeNej
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/ZHcXCRT2Zl
RT @danielevanbauer: Our paper is out in print! BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/C5D…
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/597mQdx0q8
分子生物学: BCL11Aエンハンサーの破壊解析(Nature): BCL11Aは、成体で胎児型グロビン遺伝子の発現を抑制する転写抑制因子であり、βサラセミアや鎌状赤血球病などのβグロビン症に対する有望な治療標的候補で... https://t.co/iyRJvorpyK
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/b58flFtbjw
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/RVyu3id7Zg
RT @danielevanbauer: Our paper is out in print! BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/C5D…
Nature ハイライト:BCL11Aエンハンサーの破壊解析 https://t.co/nXGZsmgi93 #分子生物学
RT @danielevanbauer: Our paper is out in print! BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/C5D…
Our paper is out in print! BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis https://t.co/C5DYMYhEm8
Dan Bauer @BostonChildrens shares how #CRISPR can be used to induce fetal hemoglobin expression. https://t.co/ELaZUBkBQ6 #Thalassemia2015
Better reading late than never. Cool paper characterizing enhancer functional sequences by a CRISPR approach http://t.co/nc7iLPcrcB
RT @danielevanbauer: our in situ enhancer bashing paper is out http://t.co/bN7OwLiCjA
BCL11A & HbF. Amazing story from GWAS -> noncoding variant in enhancer -> therapeutic genome editing for sickle cell http://t.co/WE9XowCPdy
RT @SylviaBorska: #Geneediting for sickle cell https://t.co/69UbLjYCqD via @harvardmed source: @nature http://t.co/Jez80kOQmQ #CRISPR http:…
Phenomenal science. Genome editing to increase fetal hemoglobin - potential cure for sickle cell disease http://t.co/n6BIZeDVnC
RT @Magda_Skipper: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/XQlpcwVTFJ @nature
RT @GenomeBiology: Bauer &co dissect Bcl11a by CRISPR/Cas http://t.co/NzvyKEyLeU and Liu, Teichmann &co by single cell RNA-seq http://t.co/…
RT @Magda_Skipper: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/XQlpcwVTFJ @nature
RT @Magda_Skipper: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/XQlpcwVTFJ @nature
RT @Magda_Skipper: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/XQlpcwVTFJ @nature
Bauer &co dissect Bcl11a by CRISPR/Cas http://t.co/NzvyKEyLeU and Liu, Teichmann &co by single cell RNA-seq http://t.co/bOLUeKUXBx #genomics
RT @Magda_Skipper: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/XQlpcwVTFJ @nature
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/XQlpcwVTFJ @nature
RT @juliemakani: Gene editing:Treating #sicklecell disease. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http…
RT @loops_enhancers: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. http://t.co/OPjLLhmY2I
RT @loops_enhancers: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. http://t.co/OPjLLhmY2I
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. http://t.co/OPjLLhmY2I
#BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis #NCBI #POPPAM15 @powerofpain @BarbyIngle http://t.co/E5VyK6ivQy
analysis of BCL11A enhancer function by CRISPR mutagenesis @nature http://t.co/Echf0HpaMl #SciRoundup from @ScacheriLab & @TesarLabCWRU
RT @benoitbruneau: This is totally cool: Cas9-mediated enhancer dissection. Want. http://t.co/E2hGRAHd6w
Gene editing:Treating #sicklecell disease. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/UTOiuiCcBG
RT @benoitbruneau: This is totally cool: Cas9-mediated enhancer dissection. Want. http://t.co/E2hGRAHd6w
RT @benoitbruneau: This is totally cool: Cas9-mediated enhancer dissection. Want. http://t.co/E2hGRAHd6w
RT @Addgene: Plasmids avbl @Addgene: @GaetanBurgio Functional genomics dissection of enhancers w/ #CRISPR http://t.co/pVndvuLBZt http://t.c…
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/LwJMi4qIwL
CRISPR mediated targeting of BCL11A enhancer loci to reexpress HbF for the β-haemoglobinopathies. http://t.co/wIQJUO2I87 @lucapinello
RT @GholsonLyon: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/kHEAgtccqg
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/K49new6M4P
RT @joe_pickrell: Cool basic biology of a BCL11A enhancer (also a target for therapeutic genome editing) via CRISPR mutagenesis http://t.co…
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. http://t.co/DhfUTtqu1t http://t.co/QORcpPL8CF
Pubmed: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. http://t.co/Jp3l1ncwge
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. http://t.co/04Goko1zrR
RT @danielevanbauer: our in situ enhancer bashing paper is out http://t.co/bN7OwLiCjA
RT @Addgene: Plasmids avbl @Addgene: @GaetanBurgio Functional genomics dissection of enhancers w/ #CRISPR http://t.co/pVndvuLBZt http://t.c…
RT @benoitbruneau: This is totally cool: Cas9-mediated enhancer dissection. Want. http://t.co/E2hGRAHd6w
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/kHEAgtccqg
RT @obahcall: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/zLthfp4mxu
RT @obahcall: BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/zLthfp4mxu
RT @RNAiAnalyst: CRISPR as a tool to validate ZFN-targeted therapeutics? CRISPR mutagenesis characterizes BCL11A enhancer: http://t.co/H0rq…
RT @danielevanbauer: our in situ enhancer bashing paper is out http://t.co/bN7OwLiCjA
RT @RNAiAnalyst: CRISPR as a tool to validate ZFN-targeted therapeutics? CRISPR mutagenesis characterizes BCL11A enhancer: http://t.co/H0rq…
RT @joe_pickrell: Cool basic biology of a BCL11A enhancer (also a target for therapeutic genome editing) via CRISPR mutagenesis http://t.co…
RT @joe_pickrell: Cool basic biology of a BCL11A enhancer (also a target for therapeutic genome editing) via CRISPR mutagenesis http://t.co…
RT @joe_pickrell: Cool basic biology of a BCL11A enhancer (also a target for therapeutic genome editing) via CRISPR mutagenesis http://t.co…
RT @joe_pickrell: Cool basic biology of a BCL11A enhancer (also a target for therapeutic genome editing) via CRISPR mutagenesis http://t.co…
Boston Children's/Dana Farber researchers--BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/6nO5ljBIVi
RT @joe_pickrell: Cool basic biology of a BCL11A enhancer (also a target for therapeutic genome editing) via CRISPR mutagenesis http://t.co…
RT @joe_pickrell: Cool basic biology of a BCL11A enhancer (also a target for therapeutic genome editing) via CRISPR mutagenesis http://t.co…
RT @joe_pickrell: Cool basic biology of a BCL11A enhancer (also a target for therapeutic genome editing) via CRISPR mutagenesis http://t.co…
RT @benoitbruneau: This is totally cool: Cas9-mediated enhancer dissection. Want. http://t.co/E2hGRAHd6w
Plasmids avbl @Addgene: @GaetanBurgio Functional genomics dissection of enhancers w/ #CRISPR http://t.co/pVndvuLBZt http://t.co/ql85hjJy1k
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/BqAUrHXkWB
our in situ enhancer bashing paper is out http://t.co/bN7OwLiCjA
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis : Nature : Nature Publishing Group http://t.co/B5oefZTdjH
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/zLthfp4mxu
RT @RNAiAnalyst: CRISPR as a tool to validate ZFN-targeted therapeutics? CRISPR mutagenesis characterizes BCL11A enhancer: http://t.co/H0rq…
New hope for those suffering from SCD all over the world!~ Gene Editing used to Short-Circuit Sickle Cell Disease http://t.co/cZC61ZennX
CRISPR as a tool to validate ZFN-targeted therapeutics? CRISPR mutagenesis characterizes BCL11A enhancer: http://t.co/H0rqCJtfdR $SGMO
Lovely work! Functional genomics dissection of enhancers using #CRISPR mutagenesis @nature http://t.co/ZHjCv1DL6Z http://t.co/ebM2pflBzO
Researchers use CRISPR/Cas9 to short-circuit faulty hemoglobin causing sickle cell anemia http://t.co/rR134sVpV0 (I think I got that right)
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis http://t.co/R8PNLfSg8e
RT @benoitbruneau: This is totally cool: Cas9-mediated enhancer dissection. Want. http://t.co/E2hGRAHd6w
RT @benoitbruneau: This is totally cool: Cas9-mediated enhancer dissection. Want. http://t.co/E2hGRAHd6w
reading now: enhancer saturated mutagenesis with CRISPR http://t.co/7Z3RHZNeqv
RT @benoitbruneau: This is totally cool: Cas9-mediated enhancer dissection. Want. http://t.co/E2hGRAHd6w